223 related articles for article (PubMed ID: 15077912)
1. The role of somatostatin receptors in the medical treatment of acromegaly.
Vitale G; Pivonello R; Ferone D; De Martino MC; Auriemma RS; Caraglia M; Abbruzzese A; Lombardi G; Colao A
Dig Liver Dis; 2004 Feb; 36 Suppl 1():S55-9. PubMed ID: 15077912
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin agonists for treatment of acromegaly.
Ben-Shlomo A; Melmed S
Mol Cell Endocrinol; 2008 May; 286(1-2):192-8. PubMed ID: 18191325
[TBL] [Abstract][Full Text] [Related]
3. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
Öberg K; Lamberts SW
Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
Amato G; Mazziotti G; Rotondi M; Iorio S; Doga M; Sorvillo F; Manganella G; Di Salle F; Giustina A; Carella C
Clin Endocrinol (Oxf); 2002 Jan; 56(1):65-71. PubMed ID: 11849248
[TBL] [Abstract][Full Text] [Related]
6. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
Chanson P; Boerlin V; Ajzenberg C; Bachelot Y; Benito P; Bringer J; Caron P; Charbonnel B; Cortet C; Delemer B; Escobar-Jiménez F; Foubert L; Gaztambide S; Jockenhoevel F; Kuhn JM; Leclere J; Lorcy Y; Perlemuter L; Prestele H; Roger P; Rohmer V; Santen R; Sassolas G; Scherbaum WA; Schopohl J; Torres E; Varela C; Villamil F; Webb SM
Clin Endocrinol (Oxf); 2000 Nov; 53(5):577-86. PubMed ID: 11106918
[TBL] [Abstract][Full Text] [Related]
7. Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome.
Bronstein MD
Front Horm Res; 2006; 35():129-134. PubMed ID: 16809928
[TBL] [Abstract][Full Text] [Related]
8. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review.
Mazziotti G; Giustina A
Pituitary; 2010; 13(1):60-7. PubMed ID: 19189218
[TBL] [Abstract][Full Text] [Related]
9. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly.
Murray RD; Melmed S
J Clin Endocrinol Metab; 2008 Aug; 93(8):2957-68. PubMed ID: 18477663
[TBL] [Abstract][Full Text] [Related]
10. Lanreotide Autogel: a review of its use in the management of acromegaly.
Croxtall JD; Scott LJ
Drugs; 2008; 68(5):711-23. PubMed ID: 18370450
[TBL] [Abstract][Full Text] [Related]
11. Medical therapy of acromegaly: efficacy and safety of somatostatin analogues.
Feelders RA; Hofland LJ; van Aken MO; Neggers SJ; Lamberts SW; de Herder WW; van der Lely AJ
Drugs; 2009 Nov; 69(16):2207-26. PubMed ID: 19852525
[TBL] [Abstract][Full Text] [Related]
12. Pasireotide in Acromegaly: An Overview of Current Mechanistic and Clinical Data.
Samson SL
Neuroendocrinology; 2015; 102(1-2):8-17. PubMed ID: 25792118
[TBL] [Abstract][Full Text] [Related]
13. [Novel pharmacologic therapies in acromegaly].
Góth M; Hubina E; Kovács L; Szabolcs I
Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
[TBL] [Abstract][Full Text] [Related]
14. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly.
Colao A; Auriemma RS; Pivonello R
Pituitary; 2016 Apr; 19(2):210-21. PubMed ID: 26290466
[TBL] [Abstract][Full Text] [Related]
15. Lanreotide for the treatment of acromegaly.
Castinetti F; Saveanu A; Morange I; Brue T
Adv Ther; 2009 Jun; 26(6):600-12. PubMed ID: 19533047
[TBL] [Abstract][Full Text] [Related]
16. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients.
Verhelst JA; Pedroncelli AM; Abs R; Montini M; Vandeweghe MV; Albani G; Maiter D; Pagani MD; Legros JJ; Gianola D; Bex M; Poppe K; Mockel J; Pagani G
Eur J Endocrinol; 2000 Nov; 143(5):577-84. PubMed ID: 11078980
[TBL] [Abstract][Full Text] [Related]
17. The future of somatostatin analogue therapy.
Stewart PM; James RA
Baillieres Best Pract Res Clin Endocrinol Metab; 1999 Oct; 13(3):409-18. PubMed ID: 10909432
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on lanreotide Autogel in acromegaly.
Croxtall JD; Scott LJ
BioDrugs; 2008; 22(4):275-7. PubMed ID: 18611070
[TBL] [Abstract][Full Text] [Related]
19. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
[TBL] [Abstract][Full Text] [Related]
20. Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3.
Casarini AP; Pinto EM; Jallad RS; Giorgi RR; Giannella-Neto D; Bronstein MD
J Endocrinol Invest; 2006 Oct; 29(9):826-30. PubMed ID: 17114915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
